BC Platforms, a world leader in genomic data management solutions, has closed a $USD 10 million financing round led by Debiopharm Innovation Fund and Tesi, a Finnish venture capital and private equity company.
The collected funding will be used to launch new technologies integrating complex clinical and genomic data in order to deliver precision medicine and clinical patient benefits, as well as to grow BC Platforms existing genomic data management software business worldwide.
To date, the BC Platforms has established partnerships with over 50 enterprise level healthcare units and biobanks globally, representing more than 2 million subjects. BC Platforms partners with biobanks to aggregate these data for analysis to provide transformative solutions for customers across all therapeutic areas and along the entire product development life cycle.
“We are delighted to have been supported by Debiopharm Innovation Fund and Tesi in this new financing round.” says Tero Silvola, CEO at BC Platforms. “This funding will enable us to progress to our next stage of expansion and to launch our new knowledge based solutions for R&D customers worldwide. Debiopharm’s experience in drug development will provide us with invaluable insight as we launch this major new initiative.”, Silvola summarizes.
Read the full text on BC Platform’s web site